Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 17/20 | 0.67 |
| ▸ | ADRA2B | P18089 | 17/20 | 0.67 |
| ▸ | ADRA2C | P18825 | 17/20 | 0.67 |
| ▸ | ADRA1D | P25100 | 13/20 | 0.67 |
| ▸ | ADRA1B | P35368 | 11/20 | 0.67 |
| ▸ | ADRA1A | P35348 | 10/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.67 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.67 |
| ▸ | HTR1A | P08908 | 1/20 | 0.67 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.67 |
| ▸ | MAPT | P10636 | 1/20 | 0.67 |
| ▸ | HPGD | P15428 | 1/20 | 0.67 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.67 |
| ▸ | BLM | P54132 | 1/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29938904 | 1.00 | ADRA2A (0.67) | ADRA2AADRA2BADRA2CADRA1DADRA1B | |
| Povafonidine SCHEMBL6581181 | 0.84 | ADRA2A (0.67) | ADRA2AADRA2BADRA2CADRA1DADRA1B | |
| SCHEMBL7036378 | 0.84 | ADRA2A (0.67) | ADRA2AADRA2BADRA2CADRA1DADRA1B | |
| SCHEMBL7030760 | 0.84 | ADRA2A (0.67) | ADRA2AADRA2BADRA2CADRA1DADRA1B | |
| Brimonidine SCHEMBL14663814 | 0.83 | ADRA2A (0.65) | ADRA2AADRA2BADRA2CADRA1DADRA1B | |
| Povafonidine SCHEMBL8927783 | 0.83 | ADRA2A (0.66) | ADRA2AADRA2BADRA2CADRA1DADRA1B | |
| Brimonidine SCHEMBL20511531 | 0.81 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CADRA1DADRA1B | |
| Brimonidine SCHEMBL24670 | 0.81 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CADRA1DADRA1B | |
| Brimonidine SCHEMBL29374525 | 0.81 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CADRA1DADRA1B | |
| SCHEMBL6581438 | 0.81 | ADRA2A (0.50) | ADRA2AADRA2BADRA2CADRA1DADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2525793-B1 | Alpha-2 adrenergic agonist having long duration of intraocular pressure-lowering effect | ALLERGAN INC (US) | 2018-09-05 | — | — | EP | claimed |
| US-9889088-B2 | Alpha-2 adrenergic agonist having long duration of intraocular pressure-lowering effect | ALLERGAN, INC. (US) | 2018-02-13 | — | — | US | claimed |
| EP-2968277-A1 | ALPHA-2 ADRENERGIC AGONIST FOR TREATING INTRAOCULAR PRESSURE AND OCULAR DISEASES THROUGH INTRAVITREAL AND INTRACAMERAL ROUTES | ALLERGAN, INC. (US) | 2016-01-20 | — | — | EP | claimed |
| WO-2014159576-A1 | ALPHA-2 ADRENERGIC AGONIST FOR TREATING INTRAOCULAR PRESSURE AND OCULAR DISEASES THROUGH INTRAVITREAL AND INTRACAMERAL ROUTES | ALLERGAN, INC. (US) | 2014-10-02 | — | — | WO | claimed |
| US-20140275197-A1 | ALPHA-2 ADRENERGIC AGONIST FOR TREATING INTRAOCULAR PRESSURE AND OCULAR DISEASES THROUGH INTRAVITREAL AND INTRACAMERAL ROUTES | ALLERGAN, INC. (US) | 2014-09-18 | — | — | US | claimed |
| US-20130210876-A1 | ALPHA-2 ADRENERGIC AGONIST HAVING LONG DURATION OF INTRAOCULAR PRESSURE-LOWERING EFFECT | ALLERGAN, INC (US) | 2013-08-15 | — | — | US | claimed |
| WO-2011091225-A2 | ALPHA-2 ADRENERGIC AGONIST HAVING LONG DURATION OF INTRAOCULAR PRESSURE-LOWERING EFFECT | ALLERGAN, INC. (US) | 2011-07-28 | — | — | WO | claimed |
| US-20110178145-A1 | ALPHA-2 ADRENERGIC AGONIST HAVING LONG DURATION OFINTRAOCULAR PRESSURE-LOWERING EFFECT | ALLERGAN, INC. (US) | 2011-07-21 | — | — | US | claimed |
| US-12622893-B2 | Alpha2 adrenergic agonist codrugs conjugated with muscarinic agonist drugs | ADS THERAPEUTICS LLC | 2026-05-12 | — | — | US | disclosed |
| US-20240216337-A1 | ALPHA2 ADRENERGIC AGONIST CODRUGS CONJUGATED WITH MUSCARINIC AGONIST DRUGS | ADS THERAPEUTICS LLC | 2024-07-04 | — | — | US | disclosed |
| US-20240216337-A1 | ALPHA2 ADRENERGIC AGONIST CODRUGS CONJUGATED WITH MUSCARINIC AGONIST DRUGS | ADS THERAPEUTICS LLC | 2024-07-04 | — | — | US | disclosed |
| US-20240216337-A1 | ALPHA2 ADRENERGIC AGONIST CODRUGS CONJUGATED WITH MUSCARINIC AGONIST DRUGS | ADS THERAPEUTICS LLC | 2024-07-04 | — | — | US | disclosed |
| CN-117500497-A | Alpha 2 adrenergic agonist complex coupled to muscarinic agonist | ADS医疗有限责任公司 | 2024-02-02 | — | — | CN | disclosed |
| WO-2022221071-A1 | ALPHA2 ADRENERGIC AGONIST CODRUGS CONJUGATED WITH MUSCARINIC AGONIST DRUGS | ADS THERAPEUTICS LLC (US) | 2022-10-20 | — | — | WO | disclosed |
| US-6403626-B1 | USEFUL AS ANALGESIC, SEDATIVE OR ANAESTHETIC AGENTS | SYNAPTIC PHARMACEUTICAL CORPORATION | 2002-06-11 | — | — | US | disclosed |
| US-20020065307-A1 | Novel benzimidazole derivatives | SYNAPTIC PHARMACEUTICAL CORPORATION | 2002-05-30 | — | — | US | disclosed |
| US-6316637-B1 | SELECTIVE FOR CLONED HUMAN ALPHA 2 RECEPTORS AND ARE USEFUL AS ANALGESIC, SEDATIVE OR ANAESTHETIC AGENTS | SYNAPTIC PHARMACEUTICAL CORPORATION | 2001-11-13 | — | — | US | disclosed |
| EP-0775134-A4 | NOVEL BENZIMIDAZOLE DERIVATIVES | SYNAPTIC PHARMA CORP (US) | 1997-08-13 | — | — | EP | disclosed |
| EP-0775134-A1 | Imidazolin-2-ylaminobenzimidazole derivatives | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1997-05-28 | — | — | EP | disclosed |
| WO-1996004270-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1996-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020065307-A1 | Novel benzimidazole derivatives | OPRD1, OPRL1, OPRM1 | ADRA2A 123/4885ADRA2B 98/4885ADRA2C 42/4885 |
| US-20130210876-A1 | ALPHA-2 ADRENERGIC AGONIST HAVING LONG DURATION OF INTRAOCULAR PRESSURE-LOWERING EFFECT | ADRB2, ADRB1, ADRA2C | ADRA2A 4/4885ADRA2B 5/4885ADRA2C 3/4885 |
| US-20240216337-A1 | ALPHA2 ADRENERGIC AGONIST CODRUGS CONJUGATED WITH MUSCARINIC AGONIST DRUGS | ADRB2, ADRA2A, ADRA2B | ADRA2A 2/4885ADRA2B 3/4885ADRA2C 7/4885 |
| US-20110178145-A1 | ALPHA-2 ADRENERGIC AGONIST HAVING LONG DURATION OFINTRAOCULAR PRESSURE-LOWERING EFFECT | ADRB2, ADRB1, ADRA2C | ADRA2A 4/4885ADRA2B 5/4885ADRA2C 3/4885 |
| US-12622893-B2 | Alpha2 adrenergic agonist codrugs conjugated with muscarinic agonist drugs | ADRB2, ADRA1D, ADRB1 | ADRA2A 6/4885ADRA2B 8/4885ADRA2C 4/4885 |
| US-20140275197-A1 | ALPHA-2 ADRENERGIC AGONIST FOR TREATING INTRAOCULAR PRESSURE AND OCULAR DISEASES THROUGH INTRAVITREAL AND INTRACAMERAL ROUTES | ADRB2, ADRB1, ADRA2A | ADRA2A 3/4885ADRA2B 4/4885ADRA2C 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.